Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$273.88 USD
-2.45 (-0.89%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $274.09 +0.21 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Company Summary
Cambridge, MA-based Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas (STArs) – genetic medicines, cardio-metabolic disease, and hepatic infectious disease.
In August 2018, the company’s lead drug, Onpattro (patisiran), received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved treatment for this indication. In November 2019, the FDA approved Givlaari (...
Company Summary
Cambridge, MA-based Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas (STArs) – genetic medicines, cardio-metabolic disease, and hepatic infectious disease.
In August 2018, the company’s lead drug, Onpattro (patisiran), received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved treatment for this indication. In November 2019, the FDA approved Givlaari (givosiran) for acute hepatic porphyria (AHP). In November 2020, the FDA approved Oxlumo (lumasiran) injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. In June 2022, the FDA approved Amvuttra (vutrisiran) for the treatment of adult patients with polyneuropathy of hATTR amyloidosis. Amvuttra is also approved by the European Commission (EC) for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Moreover, the company has developed inclisiran for hypercholesterolemia in partnership with Novartis. In December 2020, Novartis received marketing authorization for Leqvio (inclisiran) from the European Commission. In December 2021, the FDA approved Leqvio to reduce low-density lipoprotein cholesterol (LDL-C) with two doses a year. ALNY is also co-developing another candidate, zilebesiran, with Roche for the treatment of hypertension in patients at high cardiovascular risk.
Alnylam’s expertise in RNAi therapeutics and its broad intellectual property estate has allowed the company to enter into collaborations with leading pharmaceutical and life sciences companies including Regeneron, Novartis, Roche and Sanofi’s specialty care global business unit, Genzyme, among others.
Alnylam generates revenues from research collaborations, grants and licensing of the RNAi technology outside its core focus area. For 2023, Alnylam generated total revenues of $1.83 billion compared with $1.04 billion recorded in 2022.
General Information
Alnylam Pharmaceuticals, Inc
675 WEST KENDALL STREET HENRI A. TERMEER SQUARE
CAMBRIDGE, MA 02142
Phone: 617-551-8200
Fax: 617-551-8101
Email: investors@alnylam.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.50 |
Current Year EPS Consensus Estimate | -0.63 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 276.33 |
52 Week High | 287.55 |
52 Week Low | 141.98 |
Beta | 0.38 |
20 Day Moving Average | 907,519.88 |
Target Price Consensus | 288.17 |
4 Week | 0.45 |
12 Week | 12.71 |
YTD | 43.09 |
4 Week | -0.74 |
12 Week | 7.92 |
YTD | 19.68 |
Shares Outstanding (millions) | 128.38 |
Market Capitalization (millions) | 35,160.86 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | 608.62 |
PEG Ratio | NA |
vs. Previous Year | 94.12% |
vs. Previous Quarter | 75.00% |
vs. Previous Year | 107.00% |
vs. Previous Quarter | 33.48% |
Price/Book | NA |
Price/Cash Flow | NA |
Price / Sales | 15.00 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | -1.88 |
3/31/24 | -8.92 |
12/31/23 | -12.18 |
6/30/24 | 3.01 |
3/31/24 | 3.17 |
12/31/23 | 3.08 |
6/30/24 | 2.93 |
3/31/24 | 3.07 |
12/31/23 | 2.99 |
6/30/24 | -3.11 |
3/31/24 | -16.58 |
12/31/23 | -24.08 |
6/30/24 | -3.11 |
3/31/24 | -16.58 |
12/31/23 | -24.08 |
6/30/24 | -2.63 |
3/31/24 | -16.21 |
12/31/23 | -23.71 |
6/30/24 | -0.02 |
3/31/24 | -1.73 |
12/31/23 | -1.76 |
6/30/24 | 3.36 |
3/31/24 | 3.39 |
12/31/23 | 2.98 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |